Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Shy Drager syndrome was the name for the condition now known as multiple system atrophy (MSA), a neurological condition first recognized in the 1960s. It was traditionally diagnosed when someone began ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...
Amid his absence on FOX 2 News in the morning, Tim Ezell is sharing the latest on his health journey after a trip to the Mayo ...
α-synuclein is a neuronal protein involved in functions like vesicle trafficking and neurotransmitter release. It is typically found in abundance in a healthy brain. However, the aggregation of ...
Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy PR Newswire YOKNEAM, Israel, May 19, 2025 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback